Ironwood Ends US$265 M Gout Collaboration with AstraZeneca
By Michelle Liu & Heather Cartwright
Pharma Deals Review: Vol 2018 Issue 9 (Table of Contents)
Published: 14 Sep-2018
DOI: 10.3833/pdr.v2018.i9.2357 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
After just 2 years, Ironwood Pharmaceuticals has decided to terminate its licence agreement with AstraZeneca to develop, commercialise and manufacture products containing lesinurad as an active ingredient, including Duzallo® (lesinurad/allopurinol) and Zurampic® (lesinurad), in the US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS